ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.80684
0.04%
Brent Oil
79.605
-0.76%
Bitcoin
108,335.48
5.06%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Krystal Biotech Inc (KRYS) Cotización

Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

NASDAQ
148.39
3.58
(2.47%)
Cerrado 20 Enero 3:00PM
Delayed by 15 minutes
148.39
0.17
(0.11%)
Fuera de horario: 3:12PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
148.39
Postura de Compra
114.20
Postura de Venta
158.00
Volume Operado de la Acción
180,087
145.87 Rango del Día 149.15
107.50 Rango de 52 semanas 219.34
Capitalización de Mercado [m]
4.268B
Precio Anterior
144.81
Precio de Apertura
147.04
Hora
7
@
148.24
Última hora de negociación
Volumen financiero
US$ 26,605,834
Precio Promedio Ponderado
147.7388
Volumen promedio (3 m)
277,722
Acciones en circulación
28,760,548
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
389.95
Beneficio por acción (BPA)
0.38
turnover
50.7M
Beneficio neto
10.93M

Acerca de Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.krystalbio.com
Sede
Wilmington, Delaware, USA
Fundado
-
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was US$144.81. Over the last year, Krystal Biotech shares have traded in a share price range of US$ 107.50 to US$ 219.34.

Krystal Biotech currently has 28,760,548 shares in issue. The market capitalisation of Krystal Biotech is US$4.16 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 389.95.

Flujo de Opciones Krystal Biotech (KRYS)

Ver flujo de opciones completo

Flujo General

Pesimista

Prima Neta

-3M

Calls / Puts

28.57%

Comp. / Vent.

80.00%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

KRYS Últimas noticias

Más noticias

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically...

14 Enero 2025
GlobeNewswire Inc.

Form 8-K - Current report

18 Diciembre 2024
Edgar (US Regulatory)

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful...

18 Diciembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 Diciembre 2024
Edgar (US Regulatory)

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and...

12 Diciembre 2024
GlobeNewswire Inc.

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the...

09 Diciembre 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and...

27 Noviembre 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Stifel 2024 Healthcare Conference

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

12 Noviembre 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

06 Noviembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

04 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-5-3.25966490645153.39157.01141.72375148147.6461504CS
4-10.81-6.79020100503159.2165.98141.72287043155.37570301CS
12-28.23-15.983467331176.62207.84141.72277722171.91212149CS
26-57.82-28.0393773338206.21219.34141.72252495181.09287554CS
5223.2318.5602428891125.16219.34107.5322481169.38935411CS
15686.3138.99178611762.09219.3447.67259643123.72900829CS
26095.79182.1102661652.6219.3433.0848227854103.48605349CS

KRYS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Krystal Biotech?
El precio actual de las acciones de Krystal Biotech es US$ 148.39
¿Cuántas acciones de Krystal Biotech están en circulación?
Krystal Biotech tiene 28,760,548 acciones en circulación
¿Cuál es la capitalización de mercado de Krystal Biotech?
La capitalización de mercado de Krystal Biotech es USD 4.16B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Krystal Biotech?
Krystal Biotech ha negociado en un rango de US$ 107.50 a US$ 219.34 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Krystal Biotech?
El ratio precio/beneficio de Krystal Biotech es 389.95
¿Cuál es el ratio de efectivo a ventas de Krystal Biotech?
El ratio de efectivo a ventas de Krystal Biotech es 84.08
¿Cuál es la moneda de reporte de Krystal Biotech?
Krystal Biotech presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Krystal Biotech?
El último ingresos anual de Krystal Biotech es USD 50.7M
¿Cuál es el último beneficio anual de Krystal Biotech?
El último beneficio anual de Krystal Biotech es USD 10.93M
¿Cuál es la dirección registrada de Krystal Biotech?
La dirección registrada de Krystal Biotech es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Krystal Biotech?
La dirección del sitio web de Krystal Biotech es www.krystalbio.com
¿En qué sector industrial opera Krystal Biotech?
Krystal Biotech opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

KRYS Discussion

Ver más
Monksdream Monksdream 3 meses hace
KRYS. Under $200
👍️0
Monksdream Monksdream 6 meses hace
KRYS new 52 week high
👍️0
Monksdream Monksdream 9 meses hace
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 9 meses hace
KRYS over $30
👍️0
Monksdream Monksdream 11 meses hace
KRYS new 52 week high
👍️0
Monksdream Monksdream 2 años hace
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 años hace
Moving nicely today...
👍️0
wiredawg wiredawg 3 años hace
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 años hace
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 años hace
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 años hace
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 años hace
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 años hace
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 años hace
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 años hace
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 años hace
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 años hace
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 años hace
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 años hace
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 años hace
3rd post
👍️0
crudeoil24 crudeoil24 3 años hace
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 años hace
..
👍️0

Su Consulta Reciente

NASDAQ
KRYS
Krystal Biotech
BOV
XPBR31T
XP
BOV
TRIS3
TRISUL ON
BIT
S31841
Societe Generale Effekten
BIT
S5SPOT
Societe Generale Effekten
COIN
AGCUSD
AdGroupCoin
BIT
P1Q5N5
BNP Paribas Issuance
BIT
STOX5L
SG ISSUER
BIT
P1QPU3
BNP Paribas Issuance
BIT
P1RRH4
BNP Paribas Issuance
BIT
S28237
Societe Generale Effekten
CSE
ESAU
ESGold
AMEX
KJUN
Innovator US Small Cap P...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados